In this video interview, Dr Jeffrey Kirshner from the Haematology-Oncology Associates of Central New York Community Clinical Oncology Programme talks about a global review of data on quality of life in patients on immunotherapy that was presented at this year’s ESMO. During the interview, Dr Kirshner mentions that quality of life is better with immunotherapy than […]
Two online surveys presented at the European Society of Medical Oncology (ESMO) outlined the extent to which the COVID-19 pandemic has affected burnout, job performance, and wellbeing in the global oncology workforce. The first survey included 1520 people from 101 countries between 16 April and 3 May 2020. Of these, 38% stated that they had […]
In a paper presented at this year’s European Society of Medical Oncology (ESMO) 2020 virtual congress, Dr Zeynep Zengin from City of Hope Hospital, Los Angeles, USA presented the results of a study using a commercially available circulating tumour DNA (ctDNA) assay. Assessment of ctDNA is a non-invasive method to assess genetic alterations in tumours. […]
Yesterday, findings from the phase 2 biomarker trial, BIONIKK, were presented at the European Sociaety of Medical Oncology (ESMO) virtual congress. The study showed clinical evidence that biomarker-guided first-line therapy could be used to enrich responses in patients with metastatic clear cell renal cell carcinoma (RCC). The trial included 154 patients treated with nivolumab or […]
At the European Society of Medical Oncology (ESMO) Virtual Congress 2020, Dr Cristina Suarez from the Hospital Universitari Vall D’Hebron and Vall D’Hebron Institute of Oncology in Barcelona, Spain presented an update of the clinical data from the phase 2 study of oral HIF-2a MK-6482 in Von Hippel-Lindau disease-associated cancers. Von Hippel-Lindau disease is a […]
Non-clear cell renal cell carcinoma (RCC) accounts for about 25% of all RCC diagnoses and usually has worse outcomes than clear cell RCC. Both cabozantinib and immune checkpoint inhibitors have shown preliminary activity in non-clear cell RCC. Cabozantinib appears to enhance the response to immune checkpoint inhibitors and has shown encouraging results in combination with […]
At the European Society of Medical Oncology (ESMO) Virtual Congress 2020, Dr Choueiri from Dana Farber Cancer Institute in Boston, USA presented the results of the phase 3 CheckMate-9ER trial evaluating the combination of nivolumab and cabozantinib compared to sunitinib in the first-line treatment of patients with advanced or metastatic renal cell carcinoma (RCC). Each […]
Over the past 2 years, the use of combination therapies for the first-line treatment of metastatic renal cell carcinoma (RCC) has become the standard of care for these patients. The first combination was nivolumab plus ipilimumab, which demonstrated a survival benefit over sunitinib in patients with intermediate and poor risk metastatic RCC (CheckMate-214). Shortly after, […]
The European Society for Medical Oncology (ESMO) has released a consensus statement about the management of cancer patients during the COVID-19 pandemic. An international consortium was established to discuss clinical evidence and to provide expert advice. The steering committee addressed significant clinical questions from diagnosis to surgery. The statements were discussed and voted upon The […]
The use of artificial intelligence (AI) in clinical practice using immunotherapy to treat cancer (immuno-oncology) is still in its infancy. However, AI has potential for overcoming some of the current challenges in immuno-oncology. Professor Thomas Powles, St Bartholomew’s Hospital, London, and Professor Pedro Romero, UNIL Ludwig Institute for Cancer Research, Lausanne, Switzerland discussed the promises […]
Copyright 2017 Kidney Cancer Support Network- Douglass Digital | Cambridge Web Design
